Aclarion, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.8M
- Price
- $2.35
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.62%
- Volume
- 10.4K
About
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
Quick stats
Shares outstanding2.9M
Computed float2.9M
Float / shares100.0%
Cash runway (months)15.2
Key info
SectorHealthcare
IndustryMedical - Healthcare Information Services
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001635077
Websitehttps://www.aclarion.com
AI Summary
AI-generated1/29
minorbullishclinical trial
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
Aclarion added NYU Langone Health as the eleventh clinical site in its CLARITY trial network for Nociscan.
The CLARITY study is a 300-patient, prospective, randomized, multi-center trial evaluating Nociscan in patients undergoing fusion or TDR surgery for discogenic low back pain, with a 12-month VAS Back primary endpoint.
NYU Langone's Spine Center, ranked No. 1 in neurology and neurosurgery by U.S. News & World Report, serves more than 25,000 patients annually — a high-volume enrollment asset, though the announcement carries no new data.